The physiology of cardiovascular disease and innovative liposomal platforms for therapy

Heart disease remains the major cause of death in males and females, emphasizing the need for novel strategies to improve patient treatment and survival. A therapeutic approach, still in its infancy, is the development of site-specific drug-delivery systems. Nanoparticle-based delivery systems, such as liposomes, have evolved into robust platforms for site-specific delivery of therapeutics. In this review, the clinical impact of cardiovascular disease and the pathophysiology of different subsets of the disease are described. Potential pathological targets for therapy are introduced, and promising advances in nanotherapeutic cardiovascular applications involving liposomal platforms are presented.

[1]  B. Poindexter,et al.  Cytokines increase neonatal cardiac myocyte calcium concentrations: the involvement of nitric oxide and cyclic nucleotides. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  Jiaquan Xu,et al.  Deaths: preliminary data for 2011. , 2012 .

[3]  Effect of Fe3O4-magnetic nanoparticles on acute exercise enhanced KCNQ1 expression in mouse cardiac muscle , 2010, International journal of nanomedicine.

[4]  N. Poulter,et al.  A hypothesis for the pathogenesis of essential hypertension: the initiating factors , 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[5]  T. Brümmendorf,et al.  Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part , 2011, British Journal of Cancer.

[6]  R. Virmani,et al.  Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma , 2008, Arteriosclerosis, Thrombosis and Vascular Biology.

[7]  P. Cullis,et al.  Developments in liposomal drug delivery systems , 2001, Expert opinion on biological therapy.

[8]  V. P. Whittaker,et al.  Negatively Stained Lipoprotein Membranes , 1963, Nature.

[9]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[10]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[11]  S. Prabhu.  Cytokine-Induced Modulation of Cardiac Function , 2004, Circulation research.

[12]  E. Chi,et al.  Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. , 1998, The Journal of thoracic and cardiovascular surgery.

[13]  L Biganzoli,et al.  EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Shah,et al.  Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. , 2003, Circulation.

[15]  Jie Xue,et al.  Biomimetic glycoliposomes as nanocarriers for targeting P-selectin on activated platelets. , 2007, Bioconjugate chemistry.

[16]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[17]  A. Matsumori,et al.  Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.

[18]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[19]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[20]  Fabian Kiessling,et al.  Nanotheranostics and image-guided drug delivery: current concepts and future directions. , 2010, Molecular pharmaceutics.

[21]  S. Ganta,et al.  A review of stimuli-responsive nanocarriers for drug and gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[22]  S. Litwin,et al.  Dyssynchronous Ca2+ Sparks in Myocytes From Infarcted Hearts , 2000, Circulation research.

[23]  Y. Qiu,et al.  Biomimetic engineering of non-adhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers , 1998, Nature.

[24]  Tal Dvir,et al.  Nanoparticles targeting the infarcted heart. , 2011, Nano letters.

[25]  Lung-Chi Chen,et al.  Inhaled nickel nanoparticles alter vascular reactivity in C57BL/6 mice , 2010, Inhalation toxicology.

[26]  Eorge,et al.  CARDIAC-SPECIFIC TROPONIN I LEVELS TO PREDICT THE RISK OF MORTALITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES , 2000 .

[27]  B. Sikic,et al.  Liposomal protection of adriamycin-induced cardiotoxicity in mice. , 1980, Cancer research.

[28]  J. Cleland,et al.  Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH , 2002, European journal of heart failure.

[29]  D. Larson,et al.  IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[30]  J. Fransen,et al.  Cloning and characterization of mCRIP2, a mouse LIM‐only protein that interacts with PDZ domain IV of PTP‐BL , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[31]  S. Oparil,et al.  Essential Hypertension : Part I : Definition and Etiology , 1999 .

[32]  M. Berndt,et al.  Platelet physiology and thrombosis. , 2004, Thrombosis research.

[33]  I. Ali,et al.  Advances in nano drugs for cancer chemotherapy. , 2011, Current cancer drug targets.

[34]  J. Mehta,et al.  Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. , 2006, American journal of physiology. Heart and circulatory physiology.

[35]  James O. Mudd,et al.  An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .

[36]  E. Fontaine,et al.  Myocardial reactive hyperemia in experimental chronic heart failure: evidence for the role of K+ adenosine triphosphate-dependent channels and cyclooxygenase activity. , 1997, Journal of cardiac failure.

[37]  M. A. Holgado,et al.  Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules. , 2012, Current medicinal chemistry.

[38]  F. Clubb,et al.  Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits , 2010, Vascular medicine.

[39]  Zhiwei Hu,et al.  Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Dellian,et al.  Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels , 2003, International journal of cancer.

[41]  G. Gregoriadis,et al.  Morphological observations on the cellular and subcellular destination of intravenously administered liposomes. , 1974, British journal of experimental pathology.

[42]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[43]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[44]  Dexi Liu,et al.  Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. , 1995, Biochimica et biophysica acta.

[45]  Reid Kb,et al.  Activation and control of the complement system. , 1986 .

[46]  D. McPherson,et al.  Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia. , 2009, Journal of the American College of Cardiology.

[47]  E. Ruoslahti,et al.  Molecular Profiling of Heart Endothelial Cells , 2005, Circulation.

[48]  N. Frangogiannis,et al.  The role of IL-1 in the pathogenesis of heart disease , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[49]  D. Mann,et al.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[51]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[52]  C. Smith,et al.  Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody. , 1996, The American journal of pathology.

[53]  K. Reid,et al.  Activation and control of the complement system. , 1986, Essays in biochemistry.

[54]  Michael Ginsberg,et al.  Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[56]  N. Leitinger.  Oxidized phospholipids as modulators of inflammation in atherosclerosis , 2003, Current opinion in lipidology.

[57]  J. Qi,et al.  Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model. , 2008, Biomaterials.

[58]  L. Thompson,et al.  Changes in cardiopulmonary function induced by nanoparticles. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[59]  T. King,et al.  Temporal effects of cytokines on neonatal cardiac myocyte Ca2+ transients and adenylate cyclase activity. , 1997, The American journal of physiology.

[60]  R. Parish,et al.  Inflammation in Chronic Heart Failure , 2008, The Annals of pharmacotherapy.

[61]  Anna Strömberg,et al.  ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE 2008 (ENDING) , 2009 .

[62]  Rekha Srinivasan,et al.  In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. , 2009, Journal of biomedical materials research. Part A.

[63]  Sara M Weis,et al.  Vascular permeability in cardiovascular disease and cancer , 2008, Current opinion in hematology.

[64]  J. Leor,et al.  Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair , 2011, Proceedings of the National Academy of Sciences.

[65]  A. Deng,et al.  Pressure Overload-induced Cardiac Remodeling and Dysfunction in the Absence of Interleukin 6 in Mice , 2012, Laboratory Investigation.

[66]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[67]  J. Krupiński,et al.  Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective , 2011, Vascular cell.

[68]  Mauro Ferrari,et al.  Nanomedicine in cancer therapy: Innovative trends and prospects , 2011, Cancer science.

[69]  James Margolis,et al.  Systemic Nanoparticle Paclitaxel (nab‐Paclitaxel) for In‐stent Restenosis I (SNAPIST‐I): A First‐in‐Human Safety and Dose‐finding Study , 2007, Clinical cardiology.

[70]  V. Petrov,et al.  Induction of cardiac fibrosis by transforming growth factor-beta(1). , 2000, Molecular genetics and metabolism.

[71]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[72]  Jose H. Flores-Arredondo,et al.  Immune Modulation in Heart Failure: Past Challenges and Future Hopes , 2011, Current Heart Failure Reports.

[73]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[74]  D. Fraker,et al.  Tumor Necrosis Factor-alpha Damages Tumor Blood Vessel Integrity by Targeting VE-Cadherin , 2006, Annals of surgery.

[75]  C. Mackay,et al.  Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. , 1997, Circulation.

[76]  M. Gawaz,et al.  A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion Formation , 2002, The Journal of experimental medicine.

[77]  N. Frangogiannis,et al.  Transforming growth factor (TGF)-β signaling in cardiac remodeling. , 2011, Journal of molecular and cellular cardiology.

[78]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Thomas K Borg,et al.  Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. , 2007, American journal of physiology. Heart and circulatory physiology.

[80]  G. Palleschi,et al.  Cardiac autonomic regulation after lung exposure to carbon nanotubes , 2009, Human & experimental toxicology.

[81]  James O. Mudd,et al.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. , 2000, The Journal of clinical investigation.

[82]  M. Law,et al.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. , 2003, Health technology assessment.

[83]  K. Huber,et al.  Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication , 2005, Journal of thrombosis and haemostasis : JTH.

[84]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[85]  M. Shive,et al.  Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[86]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[87]  L. Mahakian,et al.  The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[88]  Viness Pillay,et al.  A Review on Composite Liposomal Technologies for Specialized Drug Delivery , 2011, Journal of drug delivery.

[89]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[90]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[91]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[92]  Wei Liu,et al.  IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. , 2009, Experimental and molecular pathology.

[93]  J. Perrard,et al.  Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart. , 1994, Circulation.

[94]  G Gregoriadis,et al.  Drug-carrier potential of liposomes in cancer chemotherapy. , 1974, Lancet.

[95]  R. Becker.  Thrombosis and the role of the platelet. , 1999, The American journal of cardiology.

[96]  V. Castranova,et al.  Cell Permeability, Migration, and Reactive Oxygen Species Induced by Multiwalled Carbon Nanotubes in Human Microvascular Endothelial Cells , 2012, Journal of toxicology and environmental health. Part A.

[97]  T. Ueland,et al.  TNF Revisited: Osteoprotegerin and TNF-related Molecules in Heart Failure , 2012, Current Heart Failure Reports.

[98]  C. Cairns,et al.  Ischemia Alone is Sufficient to Induce TNF-&agr; mRNA and Peptide in the Myocardium , 2002, Shock.

[99]  Michael Joner,et al.  Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.

[100]  Philip J. Barter,et al.  The role of HDL-cholesterol in preventing atherosclerotic disease , 2005 .

[101]  Manabu T. Nakamura,et al.  Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits , 2010, Experimental biology and medicine.

[102]  D. Cheresh,et al.  Tyrosine Phosphorylation of VE-cadherin Prevents Binding of p120- and β-Catenin and Maintains the Cellular Mesenchymal State* , 2005, Journal of Biological Chemistry.

[103]  W. Gonzalez,et al.  Mechanisms of L-Type Ca2+ Current Downregulation in Rat Atrial Myocytes During Heart Failure , 2001, Circulation research.

[104]  M. Sekiguchi,et al.  Coronary thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. , 1978, British heart journal.

[105]  J. Borén,et al.  Subendothelial retention of atherogenic lipoproteins in early atherosclerosis , 2002, Nature.

[106]  L. Becker.  Myocardial Reperfusion Injury , 2004, Journal of Thrombosis and Thrombolysis.

[107]  F. Burzotta,et al.  Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[108]  H. Ly,et al.  Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. , 2008, Journal of the American College of Cardiology.

[109]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[110]  M. Ferrari,et al.  What does physics have to do with cancer? , 2011, Nature Reviews Cancer.

[111]  T. Tominaga,et al.  Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. , 2011, Journal of neurosurgery.

[112]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[113]  W. Dreyer,et al.  Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. , 1992, Circulation research.